| Filed On | Filing |
|---|---|
| 29 Sep 2026 |
8-K: Other Events
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 |
| 02 Sep 2026 |
Form 4: Sheffield Ian, Director
Granted 100,000 Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 3: Sheffield Ian, Director
No securities owned |
| 01 Sep 2026 |
Form 4: Elia Marc, Director
Granted 10,700,000 Stock Option (Right to Buy) |
| 01 Sep 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Other Events |
| 18 Aug 2026 |
Form 4: Lee Timothy Edward, Chief Commercial Officer
Received 102,000 shares by exercise or conversion · Sold 22,355 shares ($16.1K) · Sold 18,425 shares ($15.5K) |
| 18 Aug 2026 |
Form 4: Green Julie, Chief Human Resources Officer
Received 102,000 shares by exercise or conversion · Sold 22,355 shares ($16.1K) · Sold 18,425 shares ($15.5K) |
| 18 Aug 2026 |
Form 4: Duke William E., Chief Financial Officer
Received 102,000 shares by exercise or conversion · Sold 22,355 shares ($16.1K) · Sold 18,425 shares ($15.5K) |
| 18 Aug 2026 |
Form 4: Andersen Jill, Chief Legal Officer, Secretary
Received 170,000 shares by exercise or conversion · Sold 37,256 shares ($26.9K) · Sold 30,706 shares ($25.9K) |
| 18 Aug 2026 |
Form 4: Allen Robert D. Iii, Chief Scientific Officer
Received 102,000 shares by exercise or conversion · Sold 20,679 shares ($14.9K) · Sold 17,043 shares ($14.4K) |
| 17 Aug 2026 | 144 |
| 17 Aug 2026 | 144 |
| 17 Aug 2026 | 144 |
| 17 Aug 2026 | 144 |
| 17 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 04 Aug 2026 |
Form 4: Mina Michael, CMO and Chief Epidemiologist
Granted 1,125,000 Stock Option (Right to Buy) |
Loading...
